Session Learning Objectives

  1. Understand the role of biomarker testing in NSCLC
  2. Explain the role of targeted therapies and need for second line options for patients without driver alterations
  3. Become familiar with emerging biomarkers in NSCLC and how IHC may play a role 

Session Faculty

Moises Velez, MD, is a consultant with Agilent, speaker for Sanofi.

Session date: 
06/29/2023 - 8:30am to 9:30am EDT
Location: 
Boston Medical Center
United States
See map: Google Maps
Add to calendar: 
  • 1.00 AMA PRA Category 1 Credit™

    Boston University Chobanian & Avedisian School of Medicine designates this Live activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • 1.00 Participation
Please login or register to take this course.